Skip to main content
Clinical Trials/IRCT201010124920N1
IRCT201010124920N1
Completed
未知

A therapeutic and side effects’ comparison between Reditux and brand type (MabThera) in Diffuse Large B Cell Lymphoma (DLBCL)

Cinnagen Company0 sites30 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Diffuse large B cell lymphoma (DLBCL).
Sponsor
Cinnagen Company
Enrollment
30
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • DLBCL patients 18 to 65 years old (male \& female); CD 20 marker positivity; Completion of informal consent. Exclusion criteria: Recurrence DLBCL; Systolic dysfunction (EF\<50%); HIV, HBV, HCV markers positivity; History of organ transplantation of other active malignancy; History of allergy to monoclonal antibodies; ECOG performance status \>3; Advanced Liver or renal dysfunctions (Bil T \>6 mg/dl or Cr \>4 mg/dl).

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials